Novo Nordisk Price Target Cut by BMO Capital
Analyst Lowers Target to $16, Maintains Outperform Rating
On Thursday, August 8th, 2024, BMO Capital Markets adjusted their price target on shares of Novo Nordisk (NYSE: NVO), a global healthcare company. The price target was reduced from $17.00 to $16.00, and the firm maintained an "outperform" rating on the stock.
Mid-Day Trading Performance
Shares of NVO traded up by 5.95% during mid-day trading, reaching $125.18.
Analyst's Rationale
In a research report released today, analyst Evan Seigerman from BMO Capital maintained a "Buy" rating on Novo Nordisk. The analyst cited the company's strong fundamentals and positive long-term growth prospects as reasons for their continued optimism.
Comments